Variability of antibody clones against alpha-synuclein and their use in the detection of Lewy pathology
Authors:
Dominik Hraboš 1,2; Satomi Hasegawa 1; Lucie Tučková 1; Kateřina Menšíková 2
Authors‘ workplace:
Ústav klinické a molekulární patologie, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc
1; Neurologická klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc
2
Published in:
Čes.-slov. Patol., 61, 2025, No. 2, p. 98-104
Category:
Original Article
Overview
According to the current recommended criteria for the diagnosis and staging of the Lewy body disease, it is necessary to evaluate the presence of Lewy bodies and Lewy neurites in specific areas of the brain. The most widely used staging systems assess the degree of neurodegeneration based on the distribution of Lewy pathology across specific anatomical regions of the brain, progressing in a caudo-rostral trajectory. Choosing the right antibody clone and using an optimized protocol including effective antigen retrieval is essential for the visualization of diagnostic deposits. The aim of our study was to evaluate the utility of some commercially available and widely used primary antibodies against alpha-synuclein in the context of post mortem diagnosis and staging of Lewy body disease. We focused on immunohistochemical and immunofluorescence analysis of Lewy pathology using antibodies with epitopes in all parts of the alphasynuclein polypeptide chain, including a conformation-specific clone and a clone for the detection of post-translationally modified protein.
Keywords:
Parkinson’s disease – alpha-synuclein – Lewy body disease – neurodegeneration
Sources
- Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener 2021; 16(1): 83.
- Lashuel HA. Do Lewy bodies contain alpha--synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol Dis 2020; 141: 104876.
- Cascella R, Chen SW, Bigi A, et al. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nat Commun 2021; 12(1): 1814.
- Emin D, Zhang YP, Lobanova E, et al. Small soluble α-synuclein aggregates are the toxic species in Parkinson‘s disease. Nat Commun 2022; 13(1): 5512.
- Moors TE, Mona D, Luehe S, et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol Commun 2022; 10(1): 82.
- Menšíková K, Matěj R, Colosimo C, et al. Lewy body disease or diseases with Lewy bodies? NPJ Parkinsons Dis 2022; 8(1): 3.
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson‘s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998; 95(11): 6469-6473.
- Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol 2010; 29(5): 271-288.
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol Aging 2003; 24(2): 197-211.
- Alafuzoff I, Ince PG, Arzberger T, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009; 117(6): 635-652.
- Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol 2021; 141(2):159-172.
- Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis 2020; 146:105086.
- Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281(40): 29739- 29752.
- Bhattacharjee P, Öhrfelt A, Lashley T, Blennow K, Brinkmalm A, Zetterberg H. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson‘s Disease. J Proteome Res 2019 May 3; 18(5): 2109-2120.
- Lashuel HA, Mahul-Mellier AL, Novello S, et al. Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha- -synuclein biochemical and pathological diversity. NPJ Parkinsons Dis 2022; 8(1): 136.
- Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 2008; 116(1): 37-46.
- Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol 2012; 124(1): 37-50.
- Beach TG, White CL, Hamilton RL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008; 116(3): 277-88.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2025 Issue 2
Most read in this issue
- Umělá inteligence v patologii – pokračování
- První rozhovor s novým šéfredaktorem našeho časopisu
- Machine learning in digital pathology
- Utilization of Artificial Intelligence Algorithms for the Diagnosis of Breast, Lung, and Prostate Cancer